Defining Clinical Meaningfulness in Huntington's Disease
- 5 May 2023
- journal article
- research article
- Published by Wiley in Movement Disorders
- Vol. 38 (6) , 1036-1043
Abstract
Background: Minimal clinically important difference (MCID) represents the smallest within‐person change on an outcome measure considered meaningful to the patient. Anchor‐based MCID methods evaluate the relationship between changes in an outcome measure and the patient‐reported clinical importance of that change.Objective: This study aims to estimate longitudinal MCID for clinically relevant outcome measures for individuals who have Stages 2 or 3 disease as measured by the Huntington's Disease Integrated Staging System (HD‐ISS).Methods: Data were drawn from Enroll‐HD, a large global longitudinal, observational study and clinical research platform for HD family members. We analyzed HD participants (N = 11,070) by staging group using time frames ranging from 12 to 36 months. The anchor was the physical component summary score of the 12‐item short‐form health survey. HD‐relevant motor, cognitive, and functional outcome measures were independent, external criterion outcomes. Complex analysis was conducted using multiple, independent, linear mixed effect regression models with decomposition to calculate MCID for each external criterion by group.Results: MCID estimates varied by progression stage. MCID estimates increased as stage progression increased and as the time frame increased. MCID values for key HD measures are provided. For example, starting in HD‐ISS stage 2, meaningful group change over 24 months equals an average increase of 3.6 or more points on the Unified Huntington's Disease Rating Scale Total Motor Score.Conclusions: This is the first study to examine MCID estimation thresholds for HD. The results can be used to improve clinical interpretation of study outcomes and enable treatment recommendations to support clinical decision‐making and clinical trial methodology. © 2023 International Parkinson and Movement Disorder Society.Keywords
Funding Information
- CHDI Foundation
This publication has 50 references indexed in Scilit:
- Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2012
- Minimum clinically important difference in pain, disability, and quality of life after neural decompression and fusion for same-level recurrent lumbar stenosis: understanding clinical versus statistical significanceJournal of Neurosurgery: Spine, 2012
- CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashionNeurology, 2012
- The Huntington's Disease health‐related Quality of Life questionnaire (HDQoL): a disease‐specific measure of health‐related quality of lifeClinical Genetics, 2011
- Cognitive Impairment in Huntington Disease: Diagnosis and TreatmentCurrent Neurology and Neuroscience Reports, 2011
- Neurocognitive signs in prodromal Huntington disease.Neuropsychology, 2011
- Cognitive and functional decline in Huntington's disease: Dementia criteria revisitedMovement Disorders, 2010
- Combining Anchor and Distribution-Based Methods to Derive Minimal Clinically Important Differences on the Functional Assessment of Cancer Therapy (FACT) Anemia and Fatigue ScalesJournal of Pain and Symptom Management, 2002
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992
- Measurement of health statusControlled Clinical Trials, 1989